← Back to headlines
Vistagen Therapeutics Faces Challenges After PALISADE-4 Clinical Trial Results
Vistagen Therapeutics, Inc. (VTGN) stock is facing new challenges following the release of its PALISADE-4 clinical trial results, impacting its market position.
15 Jul, 09:22 — 15 Jul, 09:22
Sources
Showing 1 of 1 sources
